Stress | Endometrial Cancer | HPV, Cancer Information Highlights, 01/21/2021

Having trouble viewing this email? View it as a Web page.

Cancer Information Highlights From the National Cancer Institute Updating you about cancer causes, prevention, screening, treatment, coping, and more   New from NCI Link between Stress and Cancer Coming Back   A new study in mice suggests that stress hormones may trigger a chain reaction that wakes up dormant cancer cells, causing tumors to form again. This study will likely open up other research into the effects of cancer treatment and stress on dormant cancer cells. Advances in Endometrial Cancer Research   NCI-funded researchers are working to advance our knowledge of endometrial cancer. Learn more about advances in identifying the signs and risk factors of this cancer to help find it early and the latest treatment research. HPV and Cancer   HPV is a virus that can cause many types of cancer. Learn more about HPV, how it causes cancer, how it spreads, screening tests that can find problems early, and the vaccine that can prevent cancer from forming. Abemaciclib May Be New Option for Early-Stage Breast Cancer Results from a large study suggest that adding the drug abemaciclib (Verzenio) may lower the chances that early-stage breast cancer will come back. Although there are effective treatments for this type of breast cancer, a portion of people are at high risk of cancer returning in the years after treatment. Understanding HPV and Pap Test Results (Formerly, Understanding Cervical Changes) Most women who have abnormal cervical screening test results do not have cervical cancer. Most have early cell changes that can be monitored or treated before cancer develops. PDQ Updates Thyroid Cancer Treatment We've revised our PDQ summary on thyroid cancer treatment with an updated section on targeted therapy. Treatment options for recurrent papillary and follicular thyroid cancer and medullary thyroid cancer were also updated. FDA Approvals Crizotinib Approved for Aggressive Lymphoma in Young People Food and Drug Administration (FDA) approval for crizotinib (Xalkori) now includes treatment of children and young adults with systemic anaplastic large cell lymphoma (ALCL) that is ALK positive and has either come back or does not respond to treatment. New Approval for Prostate Cancer We've added a new drug summary for relugolix (Orgovyx), which FDA recently approved to treat advanced prostate cancer.   Also of Interest Coronavirus: What People with Cancer Should Know This page answers many of the questions people with cancer have about the coronavirus or COVID-19. Learn more about the risks people with a cancer history may have, whether they should get the vaccine, what they should do about doctor visits, and more. Contact Us for Help Information specialists at NCI's Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892